BioPharmSignal logoBioPharmSignal

Biotech News

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

Editas Medicine (EDIT)Editas MedicineConference / presentation

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33 rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.

Related news

EDITEditas Medicine2026-09-01 13:00 EST

Editas Medicine to Participate in Upcoming Investor Conferences

ARWRArrowhead Pharmaceuticals2026-09-03 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST

BioCryst to Present at Upcoming Investor Conference

CRSPCRISPR Therapeutics2026-08-28 14:31 EST

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

PTCTPTC Therapeutics, Inc.2026-08-27 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

SANASana Biotechnology2026-09-01 20:05 EST

Sana Biotechnology to Present at September 2026 Investor Conferences

EDITEditas Medicine2026-09-09 13:00 EST

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SRPTSarepta Therapeutics2026-08-31 20:30 EST

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

RCKTRocket Pharmaceuticals2026-10-15 11:00 EST

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

View all latest news

Editas Medicine

In Vivo CRISPR Medicines Editas Medicine is developing in vivo CRISPR gene-editing therapies intended to produce durable therapeutic effects after a single administration. Following the discontinuation of its earlier reni-cel program, the company’s near-term strategy is concentrated on cardiometabolic editing. EDIT-401 EDIT-401 is...

Recent company news

EDITEditas Medicine2026-10-14 13:00 EST

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

EDITEditas Medicine2026-10-08 11:00 EST

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

EDITEditas Medicine2026-09-09 13:00 EST

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

EDITEditas Medicine2026-09-08 11:00 EST

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

EDITEditas Medicine2026-09-01 13:00 EST

Editas Medicine to Participate in Upcoming Investor Conferences

Stock data

Close
2.51 USD
Market cap
432.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States